Antraliv (Capsules) Instructions for Use

Marketing Authorization Holder

Nizhpharm JSC (Russia)

ATC Code

A05BA10 (Phospholipids)

Active Substance

Phospholipids (Grouping name)

Dosage Form

Antraliv

Capsules 300 mg: 20, 30, 40, 50, 60, or 100 pcs.

Dosage Form, Packaging, and Composition

10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
10 pcs. – blister packs (6) – cardboard packs.
10 pcs. – blister packs (10) – cardboard packs.

Clinical-Pharmacological Group

Hepatoprotective agent

Pharmacotherapeutic Group

Hepatoprotective agent

Pharmacological Action

Hepatoprotective agent; the Phospholipids included in the composition are the main elements in the structure of the cell membrane and mitochondria.

It regulates lipid and carbohydrate metabolism, improves the functional state of the liver and its detoxification function, promotes the preservation and restoration of the structure of hepatocytes; inhibits the formation of connective tissue in the liver.

Pharmacokinetics

Binding mainly to high-density lipoproteins, phosphatidylcholine enters, in particular, into liver cells.

The T_1/2 of the choline component is 66 hours, and that of unsaturated fatty acids is 32 hours.

Indications

Fatty liver dystrophy (including in diabetes mellitus); acute and chronic hepatitis, liver cirrhosis, liver cell necrosis, hepatic coma and precoma, toxic liver lesions; pregnancy toxemia; pre- and postoperative treatment, especially for operations in the hepatobiliary area; psoriasis (as an auxiliary therapy); radiation syndrome.

ICD codes

Dosage Regimen

Administer orally with a meal. Swallow capsules whole with a sufficient amount of liquid. Do not chew.

For adults and adolescents over 18 years of age, the standard dosage is two capsules ( 600 mg) three times daily.

The maximum daily dose is six capsules ( 1800 mg). Do not exceed this dose.

The duration of therapy is determined by the physician based on the indication and severity of the condition. The typical course of treatment is up to three months.

For maintenance therapy, use one capsule ( 300 mg) three times daily.

In severe cases, such as liver cirrhosis, the initial dosage may be increased. Follow the physician’s specific instructions.

For psoriasis as adjuvant therapy, administer two capsules three times daily for at least two weeks, followed by one capsule three times daily for the subsequent at least two months.

For radiation syndrome, initiate treatment with two capsules three times daily for a 10-14 day course.

Adjust the regimen for pre- and postoperative care as directed. The dosage form is for oral use only.

Adverse Reactions

From the digestive system when used in high doses – diarrhea.

From the immune systemhypersensitivity reactions, including skin allergic reactions: skin rash, skin itching, exanthema or urticaria.

Contraindications

Age under 18 years; soy intolerance; hypersensitivity to the active substance.

Use in Pregnancy and Lactation

Use during pregnancy is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus.

It is not recommended for use during breastfeeding due to the lack of data on safety of use.

Special Precautions

As the patient’s condition improves, parenteral administration is replaced by oral administration of a drug containing Phospholipids in the appropriate dosage form.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.